Mycophenolate Mofetil Accord

Mycophenolate Mofetil, the active ingredient in Mycophenolate Mofetil Accord, is an immunosuppressant presented as a tablet for oral use. It works by inhibiting lymphocyte proliferation and is employed to prevent organ transplant rejection and to treat autoimmune conditions such as lupus nephritis, helping to preserve graft function and reduce disease activity.

GNH USA supplies Mycophenolate Mofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The product complies with European Union regulatory standards.

Mycophenolate Mofetil is used in immunosuppressive regimens to manage transplant and autoimmune disease pathways.

- Organ transplant rejection: helps prevent acute and chronic rejection by suppressing the immune response. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Other autoimmune diseases (e.g., vasculitis, dermatomyositis): mitigates disease activity by limiting lymphocyte‑mediated tissue damage.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often self‑limiting. - Vomiting: occasional episodes, especially after dose initiation. - Abdominal pain: crampy discomfort in the upper abdomen. - Headache: transient, usually resolves without intervention. - Infections: increased susceptibility to bacterial, viral, or fungal infections.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia, or thrombocytopenia requiring laboratory monitoring. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatic toxicity: elevated transaminases or hepatitis. - Malignancy risk: potential increased incidence of lymphoproliferative disorders. - Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening demyelinating disease. - Pregnancy loss or fetal harm: teratogenic effects leading to miscarriage or birth defects.

Patients should be evaluated for risk factors and monitored regularly while receiving Mycophenolate Mofetil.

- Monitor blood counts: perform complete blood count weekly during the first month, then periodically. - Assess renal function: check serum creatinine and eGFR before initiation and during therapy. - Evaluate liver enzymes: monitor transaminases and bilirubin for signs of hepatotoxicity. - Avoid live vaccines: immunosuppression can lead to uncontrolled infection from live attenuated vaccines. - Pregnancy contraindication: drug is classified as Category X; discontinue before conception and advise effective contraception. - Store below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil may interact with several agents, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression increases risk of cytopenias. - Live vaccines: heightened risk of disseminated infection due to immunosuppression. - Cholestyramine or activated charcoal: can bind the drug and markedly reduce its absorption.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate exposure; adjust dosing based on therapeutic drug monitoring. - ACE inhibitors or ARBs: combined use can exacerbate renal dysfunction. - NSAIDs: concurrent use may increase risk of nephrotoxicity, especially in patients with pre‑existing renal impairment.